Controls severe or incapacitating allergic conditions. ANDA 75988, held by Chartwell Rx. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 75988 (Prednisolone Sodium Phosphate), held by Chartwell Rx, was first approved by FDA on May 25, 2004, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Prednisolone sodium phosphate oral solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prednisolone Sodium PhosphateEQ 5MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 5, 2020 | Supplement 6Manufacturing | Approved | None posted |
| Jun 9, 2005 | Supplement 3Labeling | Approved | None posted |
| May 25, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters